Page 3 - Marie Utter News Today

PTC Therapeutics, Inc. (NASDAQ:PTCT – Get Rating) CAO Christine Marie Utter sold 4,688 shares of the company’s stock in a transaction that occurred on Wednesday, March 29th. The shares were sold at an average price of $47.79, for a total value of $224,039.52. Following the sale, the chief accounting officer now owns 38,059 shares in […]

Should You Buy or Sell PTC Therapeutics Stock? Get The Latest PTCT Stock Forecast, Price Target, Earnings Estimates, Headlines, Short Interest at MarketBeat.

PTC Therapeutics, Inc. (NASDAQ:PTCT – Get Rating) CAO Christine Marie Utter sold 26,658 shares of the firm’s stock in a transaction that occurred on Monday, March 27th. The shares were sold at an average price of $45.09, for a total transaction of $1,202,009.22. Following the completion of the transaction, the chief accounting officer now owns […]

Shares of PTC Therapeutics, Inc. (NASDAQ:PTCT – Get Rating) have earned a consensus rating of “Hold” from the fourteen brokerages that are presently covering the firm, MarketBeat reports. One research analyst has rated the stock with a sell rating, five have assigned a hold rating and five have given a buy rating to the company. […]

Shares of PTC Therapeutics, Inc. (NASDAQ:PTCT – Get Rating) have received an average rating of “Hold” from the twelve brokerages that are currently covering the firm, MarketBeat.com reports. Two investment analysts have rated the stock with a sell recommendation, five have issued a hold recommendation and five have issued a buy recommendation on the company. […]

Cantor Fitzgerald restated their overweight rating on shares of PTC Therapeutics (NASDAQ:PTCT – Get Rating) in a research note published on Friday morning, Zacks.com reports. A number of other research analysts have also weighed in on PTCT. Barclays cut their target price on shares of PTC Therapeutics from $40.00 to $39.00 and set an equal […]

PTC Therapeutics (NASDAQ:PTCT – Get Rating)‘s stock had its “overweight” rating reaffirmed by equities research analysts at Cantor Fitzgerald in a report issued on Friday, Zacks.com reports. Other analysts also recently issued research reports about the stock. JPMorgan Chase & Co. increased their target price on shares of PTC Therapeutics from $70.00 to $76.00 and […]

Cantor Fitzgerald reissued their overweight rating on shares of PTC Therapeutics (NASDAQ:PTCT – Get Rating) in a report released on Friday, Zacks.com reports. Several other research firms also recently commented on PTCT. Zacks Investment Research downgraded shares of PTC Therapeutics from a buy rating to a sell rating in a report on Wednesday, January 26th. […]

PTC Therapeutics, Inc. (NASDAQ:PTCT – Get Rating) has earned a consensus recommendation of “Hold” from the ten analysts that are presently covering the company, MarketBeat.com reports. Two investment analysts have rated the stock with a sell rating, four have given a hold rating and four have issued a buy rating on the company. The average […]